Trials / Completed
CompletedNCT00041496
Prevention Of Recurrence Of Atrial Fibrillation
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 520 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-207266 | White, oval, biconvex tablets containing either 10mg, 25mg or 40mg |
| OTHER | Placebo | Placebo to match SB-207266 |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2003-12-01
- Completion
- 2003-12-01
- First posted
- 2002-07-12
- Last updated
- 2014-08-11
Source: ClinicalTrials.gov record NCT00041496. Inclusion in this directory is not an endorsement.